Skip to main content

New Antibiotic Ceftobiprole Could Help Fight Resistant Staph Infections

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

THURSDAY, Sept. 28, 2023 -- New research shows that an antibiotic effective for bacterial pneumonia also appears to fight treatment-resistant staph infections.

The drug is ceftobiprole. It appeared successful in fighting methicillin-resistant staph infections, sometimes called MRSA. It showed similar benefit when tested against the antibiotic daptomycin to treat complicated Staphylococcus aureus infections.

This means it could offer another option against this common and often deadly bacterial infection, according to the research led by Duke Health in Durham, N.C.

“This is an area of true need,” Dr. Thomas Holland, associate professor at Duke University School of Medicine and chair of the study's data review committee, said in a Duke Health news release. “There has not been a new antibiotic approved for the treatment of S. aureus bacteremia for over 15 years.”

The researchers studied the antibiotics in 390 patients in 17 countries who had complicated staph infections between 2018 and 2022. Roughly half were randomly assigned to receive infusions of ceftobiprole. The other half were treated intravenously with daptomycin.

The investigators assessed safety and overall treatment success, measured as survival, clearance of bacteria from the bloodstream, symptom improvement and no new bacterial complications 70 days after treatment.

Both antibiotics performed similarly.

In the ceftobiprole group, 69.8% of patients experienced overall success. That was compared to 68.7% in the daptomycin group. Gastrointestinal issues were the most common side effect for both drugs.

“Despite a lot of work in medical science, complicated staph infections still have a 25% [death] rate at 90 days,” said study co-author Dr. Vance Fowler, a professor of medicine and molecular genetics and microbiology at Duke. “We need more options for treating these infections.”

The study was sponsored by Basilea Pharmaceutica International Ltd., which markets ceftobiprole. Ceftobiprole is not approved in the US.

The findings were published online Sept. 27 in the New England Journal of Medicine.

Sources

  • Duke Health, news release, Sept. 27, 2023

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

Tips to Staying Germ-Free at the Gym

THURSDAY, July 4, 2024 -- Going to the gym is good for your overall health, but if you and the gym aren't practicing good hygiene you could still catch a nasty illness, an expert...

Tattoo Inks Can Be Contaminated With Bacteria: Study

TUESDAY, July 2, 2024 — Getting inked could make you sick. In a first-of-its-kind study, researchers detected bacteria in commercial tattoo and permanent makeup inks...

Plane Hygiene: Staying Healthy at 35,000 Feet

SATURDAY, June 22, 2024 -- The pandemic highlighted the risk that air travel carries for the spread of infectious diseases, and that risk remains even though the health emergency...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.